DNA Corporation (CEO Go Kyung-hwan) announced that it will unveil its AI-based obesity diagnosis and prediction solution, "OBST BANK," at CES 2024, the world's largest IT and consumer electronics show, to be held in Las Vegas in January.
Founded in 2019, DNA Corporation aims to provide children with a better life and brighter future by leveraging AI-powered DNA data. After two years of research, they launched "ADHD BANK," a simple screening test for ADHD. This product was presented at CES 2023 and received an Innovation Award.
Having proven its capabilities in developing AI-powered diagnostic solutions, DNA Corporation has also successfully developed "OBST BANK (Obesity BANK)," which expands the scope of its application beyond childhood ADHD to enable early detection and personalized diagnosis of obesity. This genetic analysis kit, developed through the exploration and research of biomarkers targeting obesity patients, was selected as an AI Innovation Award winner at CES 2024 and will be unveiled at the upcoming exhibition.
Like DNA Corporation's previously unveiled ADHD BANK solution, OBST BANK is an AI-based DNA data solution that supports physician diagnosis and prognosis. Its unique feature is its ability to easily collect epidermal cells from an infant at birth and utilize them for immediate genetic analysis. A company representative explained that this will significantly contribute to research on genetically-induced obesity, such as childhood obesity.
DNA Corporation stated, "We anticipate supplying this kit to biotech companies, hospitals, and hospital IT systems companies interested in developing early prediction services based on genetic analysis." They added, "Our participation at CES 2023 was instrumental in launching the ADHD BANK global market last year. Therefore, we plan to explore partnerships and customers for distribution in the US market at CES this year."
He continued, "As a biotech company that converges AI and biotechnology, we aim to expand and add services, thereby establishing ourselves as a leader in shifting the traditional medical paradigm, centered on 'diagnosis,' to 'future-oriented preventive medicine.'" He added, "To this end, we are accelerating the development of related technologies."
[CES 2024] Cracking the Genetic Blueprint of Weight: DNA Corporation's Obesity Gene Testing Kit
CES 전시회 특집으로 미국의 Ubergizmo를 통해 보도된 기사
(omitted)
Original article: https://kr.aving.net/news/articleView.html?idxno=1786175
DNA Corporation (CEO Go Kyung-hwan) announced that it will unveil its AI-based obesity diagnosis and prediction solution, "OBST BANK," at CES 2024, the world's largest IT and consumer electronics show, to be held in Las Vegas in January.
Founded in 2019, DNA Corporation aims to provide children with a better life and brighter future by leveraging AI-powered DNA data. After two years of research, they launched "ADHD BANK," a simple screening test for ADHD. This product was presented at CES 2023 and received an Innovation Award.
Having proven its capabilities in developing AI-powered diagnostic solutions, DNA Corporation has also successfully developed "OBST BANK (Obesity BANK)," which expands the scope of its application beyond childhood ADHD to enable early detection and personalized diagnosis of obesity. This genetic analysis kit, developed through the exploration and research of biomarkers targeting obesity patients, was selected as an AI Innovation Award winner at CES 2024 and will be unveiled at the upcoming exhibition.
Like DNA Corporation's previously unveiled ADHD BANK solution, OBST BANK is an AI-based DNA data solution that supports physician diagnosis and prognosis. Its unique feature is its ability to easily collect epidermal cells from an infant at birth and utilize them for immediate genetic analysis. A company representative explained that this will significantly contribute to research on genetically-induced obesity, such as childhood obesity.
DNA Corporation stated, "We anticipate supplying this kit to biotech companies, hospitals, and hospital IT systems companies interested in developing early prediction services based on genetic analysis." They added, "Our participation at CES 2023 was instrumental in launching the ADHD BANK global market last year. Therefore, we plan to explore partnerships and customers for distribution in the US market at CES this year."
He continued, "As a biotech company that converges AI and biotechnology, we aim to expand and add services, thereby establishing ourselves as a leader in shifting the traditional medical paradigm, centered on 'diagnosis,' to 'future-oriented preventive medicine.'" He added, "To this end, we are accelerating the development of related technologies."
[CES 2024] Cracking the Genetic Blueprint of Weight: DNA Corporation's Obesity Gene Testing Kit
CES 전시회 특집으로 미국의 Ubergizmo를 통해 보도된 기사
(omitted)
Original article: https://kr.aving.net/news/articleView.html?idxno=1786175